The mitochondrial permeability transition pore (MPTP) describes an inducible activity that regulates solute exchange between mitochondrial matrix contents and the surrounding cytoplasm, which acutely leads to loss of mitochondrial inner membrane potential but eventually organelle swelling and rupture. Mitochondrial rupture due to prolonged MPTP engagement, which is often the result of ischemic cellular injury due to elevated intracellular Ca 2+ levels and reactive oxygen species, underlies regulated necrotic cell death. An understanding of the molecular constituents that generate the MPTP, as well as the other proteins that can affect it, is of profound disease relevance. However, the molecular identity of the MPTP has been the subject of a protracted scientific debate for nearly three decades. In PNAS, Alavian et al. make a strong case that the c-subunit of the F 1 F O ATP synthase forms the inner mitochondrial membrane pore of the MPTP (1).
The MPTP is a highly evolutionarily conserved pore within the inner membrane of the mitochondrion that is permeable to molecules less than 1.5 kDa in size. MPTP opening results in loss of inner membrane potential, the proton gradient and ATP production, eventually leading to mitochondrial dysfunction and cell death (2) . The existence of the MPTP was first proposed in the mid20th century with the observations that high levels of Ca 2+ could lead to mitochondrial swelling and dysfunction (3, 4) . It was not until 1988 when the first pharmacological inhibitor, cyclosporine A (CsA), was shown to inhibit MPTP opening (5) . CsA is an immunosuppressant that binds to cyclophilin proteins and inhibits their activity. Two years later, the adenine nucleotide translocator (ANT) within the inner mitochondrial membrane was hypothesized to be the pore-forming component of the MPTP (Fig. 1A) . Not only could ANT form porelike properties in reconstituted membranes, but the ANT binding agents bongkrekic acid and atractyloside, which are effectors of ADP/ATP translocation across the ANT, can either block or induce mitochondrial swelling, respectively (6) .
The next suggested component of the MPTP was the voltage-dependent anion channel (VDAC), which is highly abundant within the outer mitochondrial membrane, where it enables conductance of most solutes into the intermembrane space (7) . In 1997, the specific cyclophilin that regulated the MPTP was identified as cyclophilin D (CypD), the only known mitochondrial localized cyclophilin protein, which functions as a peptidylprolyl isomerase (8) . With these proposed components, the model predicted that the MPTP was generated as one contiguous pore spanning the intermembrane space by apposition of VDAC within the outer membrane and ANT within the inner membrane, regulated by CypD within the mitochondrial matrix ( Fig. 1A ) (9) . This model would go untested until 2004, when Kokoszka et al. determined through genetic ablation of two genes encoding ANT isoforms that it was not required for MPTP opening (10) . However, mitochondria from these null mice held twofold more Ca 2+ than WT control mitochondria, suggesting that although ANT was not the pore itself, it was still an important regulator. This report largely disproved the long-standing model of the MPTP shown in Fig. 1A , although 1 y later deletion of the gene encoding CypD (Ppif) in mice supported the basic tenet of the entire field that the MPTP was dependent on cyclophilin protein function (11, 12) ; hence, this aspect of the original model was proven correct. Indeed, mitochondria lacking CypD are desensitized to MPTP opening and mice lacking the gene encoding CypD are desensitized to various MPTP-dependent pathologies, such as ischemia reperfusion injuries across multiple tissues, as well as degenerative disorders associated with Ca 2+ overload such as muscular dystrophy (11) (12) (13) . Another suggested inner membrane pore-forming component of the MPTP was the mitochondrial phosphate carrier (PiC). PiC was initially hypothesized to be a component of the MPTP due to its ability to form a pore and bind to CypD and due to the fact that phosphate greatly influences MPTP opening (14) . See companion article on page 10580.
been disproven as being required for MPTP opening using a genetic approach in the mouse and mitochondria lacking the PiC protein (15, 16) . In 2007, gene-targeted mice lacking various isoforms of the VDAC were analyzed, which further invalidated the original model of the MPTP (Fig. 1A) , because mitochondria deficient in the VDAC protein still showed MPTP functionality (17) . These collective results spurred renewed interest in attempts to discover new candidates that constitute the inner and outer membrane pore-forming components of the MPTP.
Recently, the proapoptotic Bcl-2 family members Bax and Bak were suggested to function as the outer membrane component of the MPTP in permitting mitochondrial swelling and dysfunction (18) . Mitochondria from Bax and Bak double-deleted fibroblasts, liver, or heart were resistant to Ca 2+ -induced swelling and lacked permeability/conductivity as measured by mito-patching (18) . Hence, Bax and Bak are required as the pore-forming components within the outer membrane of the mitochondria, but this activity need not form in apposition with the inner mitochondrial membrane to generate a contiguous pore (Fig. 1B) . Thus, the new model predicts that the inner and outer mitochondrial membranes function separately in MPTP opening and that the outer membrane, in the presence of Bax or Bak, is largely permissive, whereas the inner membrane is the site of regulation (Fig. 1B) .
With respect to the final component of the MPTP, that being the identity of the inner membrane pore-forming entity, Alavian et al. present data that the c-subunit of the F 1 F O ATP synthase creates the regulated pore (Fig.  1B) . In previous supportive reports, Bonora et al. and Giorgio et al. also made a strong case for the pore residing somewhere within the F 1 F O ATP synthase (19, 20) . This concept was first proposed in 2009 due to the ability of the F 1 F O ATP synthase to bind with CypD (21). Recently, it was shown that gene silencing of isomers of the c-subunit of the ATP synthase inhibited MPTP opening (19) . In addition, CypD was shown to bind to oligomycin sensitivity-conferring protein (OSCP), the oligomycin-sensitive component of the F 1 F O ATP synthase, which triggers MPTP opening through dimerization of the F 1 F O ATP synthase (20) . Alavian et al. go even further in forming this newly proposed model in that the c-subunit itself can generate pore-forming activity in proteoliposomes, although in this state, it lacks regulation by CypD. However, when the whole ATP synthase is isolated and reconstituted, it then creates a pore that is regulated by CypD, Ca shRNAs for c-subunit isomers (ATP5G1 and ATP5G3), the authors show reduced MPTP opening and decreased neuronal cell death induced by glutamate or H 2 O 2 (1). They go on to conclude that that the F 1 β-subunit portion of the ATP synthase plays an inhibitory role on the c-subunit pore. Therefore, the authors suggest the F 1 subunit must become removed from the F O ATP synthase to induce MPTP opening. Indeed, Ca 2+ -induced swelling released c-subunit oligomers from F 1, whereas MPTP inhibitors (CsA and ADP) blocked this release (1).
Atlhough these exciting results support a novel model for the MPTP, a caveat is that the F 1 F O ATP synthase cannot explain regulation by all known MPTP effectors, such as the ANT binding agents bongkrekic acid or atractyloside, which can dramatically effect MPTP activity through altering the conformational states of ANT. One possibility is that ANT is known to be part of the ATP synthasome complex (along with PiC) in association with the F 1 F O ATP synthase, and hence ANT or PiC (phosphate regulates the MPTP) might regulate the pore-forming aspects of the c-subunit of the ATPase (Fig.  1B) . If this was indeed the case, it could suggest a secondary mechanism for CsA regulation of the presumed F 1 F O ATP synthase pore activity through ANT or even PiC, both of which bind CypD. Another minor issue for future investigation is that part of the authors' proof for the F 1 F O ATP synthase c-subunit as being the pore itself involves an shRNA-mediated knockdown of the isoforms of the c-subunit, but this manipulation could also elevate matrix ADP, which could inhibit the actual pore itself if it were not the F 1 F O ATP synthase. A final issue is the uncertain therapeutic potential of the F 1 F O ATP synthase as a target because agents that block the c-subunit pore activity should also reduce ATP production, although in certain disease situations this later effect might also be a benefit (such as with select neurodegenerative disorders). Finally, genetically testing this newly hypothesized role of the F 1 F O ATP synthase as the MPTP will be very challenging for similar reasons, but will be absolutely critical in fully validating this model.
